Praxis Precision Medicines opened lower at $342.38, compared with its previous close of $346.21. In the last trading session, the stock traded between $319.24 and $343.71. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Praxis Precision Medicines is now worth
$ 106.46
Giving a profit of
$ 6.46 (6.46%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 12 Analysts
Buy
91.67%
Hold
8.33%
Sell
0%
Markets Today
Today's Change
$-20.92 (-6.04%)
Day High
$343.71
Day Low
$319.24
Day Open
$342.38
Prev Close
$346.21
Volume
5,12,262
1W Return
14.34%
1M Return
29.34%
3M Return
-12.22%
6M Return
-1.96%
1Y Return
77.21%
Fundamentals
Market Cap ($ Mn)
9,093
PE Ratio
-
PB Ratio
7.18
PEG Ratio
-
ROE
-60.40%
ROCE
-60.40%
EPS (TTM)
$-3.37
Investment Returns
1 Week
14.34%
1 Month
29.34%
3 Months
-12.22%
6 Months
-1.96%
9 Months
0.62%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
10Nov
RBC Capital raises Praxis Precision price target to $478, maintains outperform
RBC Capital maintains Outperform rating on Praxis Precision Medicines. Price target increased from $462 to $478 by analyst Leonid Timashev.
2 days ago
15Oct
HC Wainwright reiterates Buy on Praxis Precision Medicines with $1,201 target
HC Wainwright & Co. reiterated a Buy rating on Praxis Precision Medicines. Analyst Douglas Tsao maintained the price target at $1,201. No change in rating or target from previous guidance.
28 days ago
6Oct
Praxis Precision Q2FY26 Results: Operating expenses rise to $96.9 million
Operating expenses rose to $96.9 million in Q2FY26 from $76 million in Q2FY25. Cash, cash equivalents, and marketable securities stand at $1.4 billion. FDA extended Relitrigine PDUFA target to December 27, 2026, due to major amendment. Ulixacaltamide mid-cycle review showed no efficacy issues or advisory committee plans. Company plans to restart POWER 2 and POWER 3 studies for Vermetra gene in Q4FY26.
1mo ago
13Jul
Goldman Sachs initiates coverage on Praxis with Buy rating
Goldman Sachs analyst Kevin Strang has initiated coverage on Praxis Precision Medicine with a Buy rating and a price target of $447.
4mo ago
7Jul
Praxis and Remagine partner to develop ulixacaltamide patch
Praxis Precision Medicines and Remagine Labs have partnered to develop a transdermal patch for ulixacaltamide, Praxis's essential tremor therapy. The collaboration aims to expand the drug's market reach and lifecycle management, supported by an equity investment from Praxis.
4mo ago
3Jul
Praxis grants 951 RSUs to new employees under inducement plan
Praxis Precision Medicines granted restricted stock unit awards covering an aggregate of 951 shares of common stock to five new non-executive employees on July 1, 2026. The awards were made under the 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, subject to continued employment.
